<doc>
  <docmeta id="113hr4771eh">
    <bill congress="113" type="hr" number="4771" version="eh"/>
    <revision size="14307" annotations="0" status="complete" id="4" commit-time="2014-09-26T17:14:52Z" committer="mbohmer" doc="113hr4771eh/4.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Engrossed-in-House" bill-type="olc" dms-id="H64262D40BC88475CB7B3772A22FF4AC9" public-private="public" stage-count="1"> 
<metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 HR 4771 EH: Designer Anabolic Steroid Control Act of 2014</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. House of Representatives</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/"/>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="no">I</distribution-code> 
<congress>113th CONGRESS</congress> <session>2d Session</session> 
<legis-num>H. R. 4771</legis-num> 
<current-chamber display="no">IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<legis-type>AN ACT</legis-type> 
<official-title display="yes">To amend the Controlled Substances Act to more effectively regulate anabolic steroids.</official-title> 
</form> 
<legis-body id="H550032FEDE93424A83A73D320B86FB01" style="OLC"> 
<section id="H6BBC19EF2A9247C7A4835F15BD4EC227" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the <quote>
          <short-title>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Designer Anabolic Steroid Control Act of 2014" proposed="true">Designer Anabolic Steroid Control Act of 2014</cato:entity-ref>
          </short-title>
        </quote>.</text>
    </section> 
<section id="HEB87C1E8A1964E699FDB217DE0FB01D7">
      <enum>2.</enum>
      <header>Amendments to the Controlled Substances Act</header> 
<subsection id="H4219060668CF43299B524BB005DA3D72">
        <enum>(a)</enum>
        <header>Definitions</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:102/p:41">Section 102(41) of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/802">
            <cato:entity-ref entity-type="uscode" value="usc/21/802//41">21 U.S.C. 802(41)</cato:entity-ref>
          </external-xref>)</cato:entity> is amended—</text> 
<paragraph id="HF621985D87834D82980B15437A09B5C6">
          <enum>(1)</enum>
          <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A">subparagraph (A)</cato:entity-ref>—</text> 
<subparagraph id="HDBE262A981D04199B8DF49E9C0C28238">
            <enum>(A)</enum>
            <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A/cl:xlix">clause (xlix)</cato:entity-ref>, by striking <quote>and</quote> at the end;</text>
          </subparagraph> 
<subparagraph id="HA696E11445004CEFB53FB1661641AB1C">
            <enum>(B)</enum>
            <text>by redesignating <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A/cl:xlx">clause (xlx)</cato:entity-ref> as <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A/cl:lxxv" proposed="true">clause (lxxv)</cato:entity-ref>; and</text>
          </subparagraph> 
<subparagraph id="H0BBA73395CE74F5A9078AA4E964DBF58">
            <enum>(C)</enum>
            <text>by inserting after <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A/cl:xlix">clause (xlix)</cato:entity-ref> the following:</text> 
<quoted-block display-inline="no-display-inline" id="H60710B497A3545DBABA44BB818894796" style="OLC"> 
<clause id="HA65CF299E6D446DB99E085D676814B41" indent="paragraph">
                <enum>(l)</enum>
                <text>5α-Androstan-3,6,17-trione;</text>
              </clause> 
<clause id="H63DEF77CBB19452C8059407CC7CB3EF7" indent="paragraph">
                <enum>(li)</enum>
                <text>6-bromo-androstan-3,17-dione;</text>
              </clause> 
<clause id="H8F74B99F819A4F579A89E5F177CE815E" indent="paragraph">
                <enum>(lii)</enum>
                <text>6-bromo-androsta-1,4-diene-3,17-dione;</text>
              </clause> 
<clause id="H840B97B7DC8C4729A633DC34A28AFD64" indent="paragraph">
                <enum>(liii)</enum>
                <text>4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol;</text>
              </clause> 
<clause id="H4FA45A6E6A6E420C9052FA0EFCE2C5B7" indent="paragraph">
                <enum>(liv)</enum>
                <text>4-chloro-17α-methyl-androst-4-ene-3β,17β-diol;</text>
              </clause> 
<clause id="HC485FD56BE00497B84E1F4EF0D346E87" indent="paragraph">
                <enum>(lv)</enum>
                <text>4-chloro-17α-methyl-17β-hydroxy-androst-4-en-3-one;</text>
              </clause> 
<clause id="H79C3243391D041D18AB99261A136D199" indent="paragraph">
                <enum>(lvi)</enum>
                <text>4-chloro-17α-methyl-17β-hydroxy-androst-4-ene-3,11-dione;</text>
              </clause> 
<clause id="HFEDB448698F54BBD883BA75C9F363C9F" indent="paragraph">
                <enum>(lvii)</enum>
                <text>4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol;</text>
              </clause> 
<clause id="H158C4698A69141A6BEDC642A4D6365CF" indent="paragraph">
                <enum>(lviii)</enum>
                <text>2α,17α-dimethyl-17β-hydroxy-5α-androstan-3-one;</text>
              </clause> 
<clause id="H78EA4DC064444AB587D8CD6789030070" indent="paragraph">
                <enum>(lix)</enum>
                <text>2α,17α-dimethyl-17β-hydroxy-5β-androstan-3-one;</text>
              </clause> 
<clause id="HABC395D1EB0942D79157BF72E3E749DC" indent="paragraph">
                <enum>(lx)</enum>
                <text>2α,3α-epithio-17α-methyl-5α-androstan-17β-ol;</text>
              </clause> 
<clause id="H834EBAC752D5456EA610F1661ADF97DB" indent="paragraph">
                <enum>(lxi)</enum>
                <text>[3,2-c]-furazan-5α-androstan-17β-ol;</text>
              </clause> 
<clause id="HE41FF1FAA8C246D38B1538C0C181E77B" indent="paragraph">
                <enum>(lxii)</enum>
                <text>3β-hydroxy-estra-4,9,11-trien-17-one;</text>
              </clause> 
<clause id="HDC9F6A8CB95F44688CD5F1B703272D14" indent="paragraph">
                <enum>(lxiii)</enum>
                <text>17α-methyl-androst-2-ene-3,17β-diol;</text>
              </clause> 
<clause id="HC5AA50EE227C47DD9AC33666872D1D00" indent="paragraph">
                <enum>(lxiv)</enum>
                <text>17α-methyl-androsta-1,4-diene-3,17β-diol;</text>
              </clause> 
<clause id="H35261204EB494160934E343E59B9FD89" indent="paragraph">
                <enum>(lxv)</enum>
                <text>Estra-4,9,11-triene-3,17-dione;</text>
              </clause> 
<clause id="HD907DC2C397A455CB745946FF7D9BBE7" indent="paragraph">
                <enum>(lxvi)</enum>
                <text>18a-Homo-3-hydroxy-estra-2,5(10)-dien-17-one;</text>
              </clause> 
<clause id="HFA6793B9072B445A98A2D0B298025E1D" indent="paragraph">
                <enum>(lxvii)</enum>
                <text>6α-Methyl-androst-4-ene-3,17-dione;</text>
              </clause> 
<clause id="H883345755481417BAE398DCB57D4D560" indent="paragraph">
                <enum>(lxviii)</enum>
                <text>17α-Methyl-androstan-3-hydroxyimine-17β-ol;</text>
              </clause> 
<clause id="H1F19D00C0977400181EB7547E5EBE945" indent="paragraph">
                <enum>(lxix)</enum>
                <text>17α-Methyl-5α-androstan-17β-ol;</text>
              </clause> 
<clause id="H0F6B607B868C4BA5BE90384F9CE02945" indent="paragraph">
                <enum>(lxx)</enum>
                <text>17β-Hydroxy-androstano[2,3-d]isoxazole;</text>
              </clause> 
<clause id="H4391CD6574FF4073B9CD569B74F25AD3" indent="paragraph">
                <enum>(lxxi)</enum>
                <text>17β-Hydroxy-androstano[3,2-c]isoxazole;</text>
              </clause> 
<clause id="H0D64D70C134C40548708D01C0DB1DC53" indent="paragraph">
                <enum>(lxxii)</enum>
                <text>4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5α-androstan-17β-ol;</text>
              </clause> 
<clause commented="no" display-inline="no-display-inline" id="HAAE6CB2766984FCDAD408C51D4D3892F" indent="paragraph">
                <enum>(lxxiii)</enum>
                <text>[3,2-c]pyrazole-androst-4-en-17β-ol;</text>
              </clause> 
<clause id="HF7C6710578FB4326B804C6D1BA74F953" indent="paragraph">
                <enum>(lxxiv)</enum>
                <text>[3,2-c]pyrazole-5α-androstan-17β-ol; and</text>
              </clause>
              <after-quoted-block>; and</after-quoted-block>
            </quoted-block>
          </subparagraph>
        </paragraph> 
<paragraph id="H240EB239767A4DEE85EC636F46AA7814">
          <enum>(2)</enum>
          <text>by adding at the end the following:</text> 
<quoted-block display-inline="no-display-inline" id="H80846B660E8F46D59ECFB2FA4845675A" style="OLC"> 
<subparagraph id="H30EFDA08DDE042E8A61AFEFA362CA9CB" indent="up2">
              <enum>(C)</enum> 
<clause commented="no" display-inline="yes-display-inline" id="HC212D296FC2C40CDA20A81C11848CE33">
                <enum>(i)</enum>
                <text>Subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii" proposed="true">clause (ii)</cato:entity-ref>, a drug or hormonal substance (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone) that is not listed in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A">subparagraph (A)</cato:entity-ref> and is derived from, or has a chemical structure substantially similar to, 1 or more anabolic steroids listed in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:A">subparagraph (A)</cato:entity-ref> shall be considered to be an anabolic steroid for purposes of this Act if—</text> 
<subclause id="H44D0D1DFDB314DCABEF9B1DADA9B826C" indent="up1">
                  <enum>(I)</enum>
                  <text>the drug or substance has been created or manufactured with the intent of producing a drug or other substance that either—</text> 
<item id="HEAAF26BC71444905AFA5232C2DDEB7DB">
                    <enum>(aa)</enum>
                    <text>promotes muscle growth; or</text>
                  </item> 
<item id="H5326B07A8FB2482B8249FA932C048324">
                    <enum>(bb)</enum>
                    <text>otherwise causes a pharmacological effect similar to that of testosterone; or</text>
                  </item>
                </subclause> 
<subclause id="HDFB1400279B147E89CA0E5DAB7B35487" indent="up1">
                  <enum>(II)</enum>
                  <text>the drug or substance has been, or is intended to be, marketed or otherwise promoted in any manner suggesting that consuming it will promote muscle growth or any other pharmacological effect similar to that of testosterone.</text>
                </subclause>
              </clause> 
<clause id="HB5B8C6BC6E6745BF89D378C64C8145E3" indent="up1">
                <enum>(ii)</enum>
                <text>A substance shall not be considered to be a drug or hormonal substance for purposes of this subparagraph if it—</text> 
<subclause id="H079BFEA4DD724EE2985EE58042F9992B">
                  <enum>(I)</enum>
                  <text>is—</text> 
<item id="H9DF0392FF9814FB99F9ACD7D1DDEF429">
                    <enum>(aa)</enum>
                    <text>an herb or other botanical;</text>
                  </item> 
<item id="H9CC4328BD67F4170BB96960309AB4B3E">
                    <enum>(bb)</enum>
                    <text>a concentrate, metabolite, or extract of, or a constituent isolated directly from, an herb or other botanical; or</text>
                  </item> 
<item id="HAEBCFDA8B8CB466F84F22A263EFE4361">
                    <enum>(cc)</enum>
                    <text>a combination of 2 or more substances described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii/scl:I/i:aa" proposed="true">item (aa)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii/scl:I/i:bb" proposed="true">(bb)</cato:entity-ref>;</text>
                  </item>
                </subclause> 
<subclause id="HD78B9A612C974CE2B643B3BC79B97AA3">
                  <enum>(II)</enum>
                  <text>is a dietary ingredient for purposes of the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                      <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/301">
                      <cato:entity-ref entity-type="uscode" value="usc/21/301/etseq">21 U.S.C. 301 et seq.</cato:entity-ref>
                    </external-xref>)</cato:entity>; and</text>
                </subclause> 
<subclause id="H26EFE23E9AB44686B6592192F0C324E2">
                  <enum>(III)</enum>
                  <text display-inline="yes-display-inline">is not anabolic or androgenic.</text>
                </subclause>
              </clause> 
<clause id="H2E017488564A40CEBA5C3FCF1375A5CD" indent="up1">
                <enum>(iii)</enum>
                <text>In accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:515/ss:a">section 515(a)</cato:entity-ref>, any person claiming the benefit of an exemption or exception under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41/sp:C/cl:ii" proposed="true">clause (ii)</cato:entity-ref> shall bear the burden of going forward with the evidence with respect to such exemption or exception.</text>
              </clause>
            </subparagraph>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
        </paragraph>
      </subsection> 
<subsection id="H1D152C684A694BC7A9FBBCD256B56A96">
        <enum>(b)</enum>
        <header>Classification authority</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:201">Section 201 of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/811">
            <cato:entity-ref entity-type="uscode" value="usc/21/811">21 U.S.C. 811</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by adding at the end the following:</text> 
<quoted-block display-inline="no-display-inline" id="H21723D86BAAA4F49BB28391D3E743AE8" style="OLC"> 
<subsection id="H9E7A41E785B44410854797DB2734FCBF">
            <enum>(i)</enum>
            <header>Temporary and permanent scheduling of recently emerged anabolic steroids</header> 
<paragraph id="HA5F2D61FAA3046E08F4354F4CED05B4F">
              <enum>(1)</enum>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may issue a temporary order adding a drug or other substance to the definition of anabolic steroids if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> finds that—</text> 
<subparagraph id="HB9EAF651D20F4873888EE5F41298CA89">
                <enum>(A)</enum>
                <text>the drug or other substance satisfies the criteria for being considered an anabolic steroid under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41">section 102(41)</cato:entity-ref> but is not listed in that section or by regulation of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> as being an anabolic steroid; and</text>
              </subparagraph> 
<subparagraph id="H3A78B56B2EBC4E37A4449A34289291A4">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">adding such drug or other substance to the definition of anabolic steroids will assist in preventing abuse or misuse of the drug or other substance.</text>
              </subparagraph>
            </paragraph> 
<paragraph id="H93C402EEE407475CAB1D9261DF0EC195">
              <enum>(2)</enum>
              <text>An order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall not take effect until 30 days after the date of the publication by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> of a notice in the Federal Register of the intention to issue such order and the grounds upon which such order is to be issued. The order shall expire not later than 24 months after the date it becomes effective, except that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may, during the pendency of proceedings under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:6" proposed="true">paragraph (6)</cato:entity-ref>, extend the temporary scheduling order for up to 6 months.</text>
            </paragraph> 
<paragraph id="H8CE27C3CD9F649A09C8BA7EC326CE2C4">
              <enum>(3)</enum>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> shall transmit notice of an order proposed to be issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:1" proposed="true">paragraph (1)</cato:entity-ref> to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7500" entity-type="federal-body">Secretary of Health and Human Services</cato:entity-ref>. In issuing an order under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:1" proposed="true">paragraph (1)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> shall take into consideration any comments submitted by the Secretary in response to a notice transmitted pursuant to this paragraph.</text>
            </paragraph> 
<paragraph id="H4696AD894103424D8DCBEBBF025D552B">
              <enum>(4)</enum>
              <text>A temporary scheduling order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall be vacated upon the issuance of a permanent scheduling order under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:6" proposed="true">paragraph (6)</cato:entity-ref>.</text>
            </paragraph> 
<paragraph id="HA711F6AFAB86402B930E94F6C5B0351A">
              <enum>(5)</enum>
              <text>An order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:1" proposed="true">paragraph (1)</cato:entity-ref> is not subject to judicial review.</text>
            </paragraph> 
<paragraph id="H4AE7A22957D84DC7A8175C022B3D0B84">
              <enum>(6)</enum>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may, by rule, issue a permanent order adding a drug or other substance to the definition of anabolic steroids if such drug or other substance satisfies the criteria for being considered an anabolic steroid under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:102/p:41">section 102(41)</cato:entity-ref>. Such rulemaking may be commenced simultaneously with the issuance of the temporary order issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:201/ss:i/p:1" proposed="true">paragraph (1)</cato:entity-ref>.</text>
            </paragraph>
          </subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
      </subsection>
    </section> 
<section id="H0AA6E27EC6F44B89AA78F833C32F4046">
      <enum>3.</enum>
      <header>Labeling requirements</header> 
<subsection id="H76C8DABA9CD74E46A6DD99A232B07B31">
        <enum>(a)</enum>
        <header>In general</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:305">Section 305 of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/825">
            <cato:entity-ref entity-type="uscode" value="usc/21/825">21 U.S.C. 825</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by adding at the end the following:</text> 
<quoted-block style="OLC" id="HBAF16F3548AF4B8D85346EDCDC0CB39E" display-inline="no-display-inline"> 
<subsection id="H52AE9CA84114409DA6A4DD325E2222B2">
            <enum>(e)</enum>
            <header>False Labeling of Anabolic Steroids</header> 
<paragraph id="HAD4C7D05540A4162886EF6622B3CE0F2">
              <enum>(1)</enum>
              <text display-inline="yes-display-inline">It shall be unlawful to import, export, manufacture, distribute, dispense, or possess with intent to manufacture, distribute, or dispense, an anabolic steroid or product containing an anabolic steroid, unless the steroid or product bears a label clearly identifying an anabolic steroid or product containing an anabolic steroid by the nomenclature used by the International Union of Pure and Applied Chemistry (IUPAC).</text>
            </paragraph> 
<paragraph id="H9CB90F0B8AD042088328EC737BE9A8C1" commented="no">
              <enum>(2)</enum> 
<subparagraph id="H774C3E7B83224673975DC3E064B7AC48" commented="no" display-inline="yes-display-inline">
                <enum>(A)</enum>
                <text display-inline="yes-display-inline">A product described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:305/ss:e/p:2/sp:B" proposed="true">subparagraph (B)</cato:entity-ref> is exempt from the International Union of Pure and Applied Chemistry nomenclature requirement of this subsection if such product is labeled in the manner required under the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug, and Cosmetic Act</cato:entity-ref>.</text>
              </subparagraph> 
<subparagraph id="H9F40E51E625847DDB8C0DBEC8CE37F60" indent="up1" commented="no">
                <enum>(B)</enum>
                <text>A product is described in this subparagraph if the product—</text> 
<clause id="H971F59DC427143ED96FB5EFA14EF52F0" commented="no">
                  <enum>(i)</enum>
                  <text>is the subject of an approved application as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b">section 505(b)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j">(j) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>; or</text>
                </clause> 
<clause id="H480745FCF1CE4DD1BEC8AF37CD2CBCBD" commented="no">
                  <enum>(ii)</enum>
                  <text>is exempt from the provisions of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505 of such Act</cato:entity-ref> relating to new drugs because—</text> 
<subclause id="H626141A9732141AFB4F972C9B7320FAD" commented="no">
                    <enum>(I)</enum>
                    <text>it is intended solely for investigational use as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:i">section 505(i) of such Act</cato:entity-ref>; and</text>
                  </subclause> 
<subclause id="H336FF325EC564BB09684BE9A03857740" commented="no">
                    <enum>(II)</enum>
                    <text>such product is being used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application.</text>
                  </subclause>
                </clause>
              </subparagraph>
            </paragraph>
          </subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
      </subsection> 
<subsection id="HDAEDD3F74BCB41C28ACD3FB30C5CF7F6">
        <enum>(b)</enum>
        <header>Clarification to Import and Export statute</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Import and Export Act/s:1010">Section 1010 of the Controlled Substances Import and Export Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/960">
            <cato:entity-ref entity-type="uscode" value="usc/21/960">21 U.S.C. 960</cato:entity-ref>
          </external-xref>)</cato:entity> is amended, in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Import and Export Act/s:1010/ss:a/p:1">subsection (a)(1)</cato:entity-ref>, by inserting <quote>305,</quote> before <quote>1002</quote>.</text>
      </subsection> 
<subsection id="HE01AFE24958E472B9B2C70C71FA45B2F">
        <enum>(c)</enum>
        <header>Civil penalties</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:402">Section 402 of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/842">
            <cato:entity-ref entity-type="uscode" value="usc/21/842">21 U.S.C. 842</cato:entity-ref>
          </external-xref>)</cato:entity> is amended—</text> 
<paragraph id="H21FC41F7A1D144A7BDEC4F37B6CB75C4">
          <enum>(1)</enum>
          <text display-inline="yes-display-inline">in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:402/ss:a">subsection (a)</cato:entity-ref>—</text> 
<subparagraph id="H58242EC4047C4578921004BA6ABB5868">
            <enum>(A)</enum>
            <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:402/ss:a/p:14">paragraph (14)</cato:entity-ref>, by striking <quote>or</quote> at the end;</text>
          </subparagraph> 
<subparagraph id="HA97C8240691845BC846BDB582727CF41">
            <enum>(B)</enum>
            <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:402/ss:a/p:15">paragraph (15)</cato:entity-ref>, by striking the period at the end and inserting <quote>; or</quote>; and </text>
          </subparagraph> 
<subparagraph id="H885FA92357764E209A05C727E46737E8">
            <enum>(C)</enum>
            <text>by inserting, after <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:402/ss:a/p:15">paragraph (15)</cato:entity-ref>, the following:</text> 
<quoted-block style="OLC" id="H4E1383445DF84915957CBB6DAFBC9B6D" display-inline="no-display-inline"> 
<paragraph id="H8804113A357E447FA811F300D7582303">
                <enum>(16)</enum>
                <text display-inline="yes-display-inline">to violate <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:825/ss:e">subsection (e) of section 825 of this title</cato:entity-ref>.</text>
              </paragraph>
              <after-quoted-block>; and</after-quoted-block>
            </quoted-block>
          </subparagraph>
        </paragraph> 
<paragraph id="H2BB0A17252A94CA289550DFA512C49B5">
          <enum>(2)</enum>
          <text display-inline="yes-display-inline">in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:402/ss:c/p:1">subsection (c)(1)</cato:entity-ref>—</text> 
<subparagraph id="H887D3A3120A74D8DA084EE5CE4EC42B9">
            <enum>(A)</enum>
            <text display-inline="yes-display-inline">by inserting, in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:402/ss:c/p:1/sp:A">subparagraph (A)</cato:entity-ref>, after <quote>subparagraph (B)</quote> the following: <quote>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:402/ss:c/p:1/sp:C" proposed="true">(C)</cato:entity-ref>, or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:402/ss:c/p:1/sp:D" proposed="true">(D)</cato:entity-ref>
              </quote>; and</text>
          </subparagraph> 
<subparagraph id="H489A4CF7ABCB40D5A9936B7C7677333B">
            <enum>(B)</enum>
            <text>by inserting after <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:402/ss:c/p:1/sp:B">subparagraph (B)</cato:entity-ref> the following: </text> 
<quoted-block style="OLC" id="H972FCE4C74364F24B0E33E96A426902B" display-inline="no-display-inline"> 
<subparagraph id="H744FA6A7EA6F4607BFFBEC20BD26790D" indent="up2">
                <enum>(C)</enum>
                <text display-inline="yes-display-inline">In the case of a violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:402/ss:a/p:16" proposed="true">paragraph (16) of subsection (a) of this section</cato:entity-ref> by an importer, exporter, manufacturer, or distributor (other than as provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:402/ss:c/p:1/sp:D" proposed="true">subparagraph (D)</cato:entity-ref>), up to $500,000 per violation. For purposes of this subparagraph, a violation is defined as each instance of importation, exportation, manufacturing, distribution, or possession with intent to manufacture or distribute, in violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:402/ss:a/p:16" proposed="true">paragraph (16) of subsection (a)</cato:entity-ref>.</text>
              </subparagraph> 
<subparagraph id="H86D7930D57404418BA06D849C45A2FB6" indent="up2">
                <enum>(D)</enum>
                <text display-inline="yes-display-inline">In the case of a distribution, dispensing, or possession with intent to distribute or dispense in violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:402/ss:a/p:16" proposed="true">paragraph (16) of subsection (a) of this section</cato:entity-ref> at the retail level, up to $1000 per violation. For purposes of this paragraph, the term <quote>at the retail level</quote> refers to products sold, or held for sale, directly to the consumer for personal use. Each package, container or other separate unit containing an anabolic steroid that is distributed, dispensed, or possessed with intent to distribute or dispense at the retail level in violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:402/ss:a/p:16" proposed="true">such paragraph (16) of subsection (a)</cato:entity-ref> shall be considered a separate violation. </text>
              </subparagraph>
              <after-quoted-block>.</after-quoted-block>
            </quoted-block>
          </subparagraph>
        </paragraph>
      </subsection>
    </section> 
<section id="HB64016946EA74F1E9AC51F21D1DC944A">
      <enum>4.</enum>
      <header>Identification and publication of list of products containing anabolic steroids</header> 
<subsection id="H614AE6250F2F45D984BA6CA245F86455">
        <enum>(a)</enum>
        <header>In general</header>
        <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may, in the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref>’s discretion, collect data and analyze products to determine whether they contain anabolic steroids and are properly labeled in accordance with this Act and the amendments made by this Act. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> may publish in the Federal Register or on the website of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1524" entity-type="federal-body">Drug Enforcement Administration</cato:entity-ref> a list of products which the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> has determined, based on substantial evidence, contain an anabolic steroid and are not labeled in accordance with this Act and the amendments made by this Act.</text>
      </subsection> 
<subsection id="H5E9D82B154E742048035597FC581466B">
        <enum>(b)</enum>
        <header>Absence from list</header>
        <text display-inline="yes-display-inline">The absence of a product from the list referred to in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Designer Anabolic Steroid Control Act of 2014/s:4/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall not constitute evidence that the product does not contain an anabolic steroid.</text>
      </subsection>
    </section> 
</legis-body> <attestation>
    <attestation-group>
      <attestation-date date="20140915" chamber="House">Passed the House of Representatives September 15, 2014.</attestation-date>
      <attestor display="no">Karen L. Haas,</attestor>
      <role>Clerk.</role>
    </attestation-group>
  </attestation>
<endorsement display="yes"/>
</bill>
</doc>